Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 6/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16296306 | 0.85 | PIM1 (0.44) | NOTUMRXRAGRIN1GRIN2BNPY5R | |
| SCHEMBL16303974 | 0.81 | NLRP3 (0.45) | NOTUMRXRAGRIN1GRIN2BPIM1 | |
| SCHEMBL18504510 | 0.81 | PIM1 (0.46) | PDE10ARXRAGRIN1GRIN2BNPY5R | |
| SCHEMBL16296304 | 0.80 | NOTUM (0.40) | NOTUMRXRAGRIN1GRIN2BNPY5R | |
| SCHEMBL16296402 | 0.79 | IDO1 (0.48) | NOTUM | |
| SCHEMBL16303967 | 0.78 | PIM1 (0.38) | RXRAGRIN1GRIN2BNPY5RPIM1 | |
| SCHEMBL16297209 | 0.78 | PIM1 (0.39) | RXRAGRIN1GRIN2BNPY5RPIM1 | |
| SCHEMBL16303984 | 0.78 | PIM1 (0.39) | NOTUMRXRAGRIN1GRIN2BNPY5R | |
| SCHEMBL16297293 | 0.78 | HDAC8 (0.39) | RXRAGRIN1GRIN2BNPY5RPIM1 | |
| SCHEMBL16297298 | 0.78 | AKR1C3 (0.48) | RXRAGRIN1GRIN2BPIM1SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105283452-B | Tetrazolone derivatives | 豪夫迈·罗氏有限公司 | 2019-01-04 | — | — | CN | claimed |
| EP-3008055-B1 | TETRAZOLONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | claimed |
| EP-3008055-A1 | NOVEL TETRAZOLONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-04-20 | — | — | EP | claimed |
| US-20160083357-A1 | NOVEL TETRAZOLONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-03-24 | — | — | US | claimed |
| CN-105283452-A | Novel tetrazolone derivatives | HOFFMANN LA ROCHE | 2016-01-27 | — | — | CN | claimed |
| WO-2014198592-A1 | NOVEL TETRAZOLONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-18 | — | — | WO | claimed |
| CN-105283452-B | Tetrazolone derivatives | 豪夫迈·罗氏有限公司 | 2019-01-04 | — | — | CN | disclosed |
| EP-3008055-B1 | TETRAZOLONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-3008055-A1 | NOVEL TETRAZOLONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-20160083357-A1 | NOVEL TETRAZOLONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-03-24 | — | — | US | disclosed |
| CN-105283452-A | Novel tetrazolone derivatives | HOFFMANN LA ROCHE | 2016-01-27 | — | — | CN | disclosed |
| WO-2014198592-A1 | NOVEL TETRAZOLONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083357-A1 | NOVEL TETRAZOLONE DERIVATIVES | TBXA2R, CYP11B2, NR1I2 | NOTUM 3450/4885PDE10A 3762/4885RXRA 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.